EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open access · CC BY 4.0

Patient-reported outcomes in palopegteriparatide-treated adults with hypoparathyroidism: PaTH Forward trial extension

Mishaela Rubin, Andrea Palermo iD, Tamara Vokes, Aliya A Khan, Peter Schwarz, Filomena Cetani, Uberto Pagotto iD, Elena Tsourdi, Tanja Sikjaer, Kathryn M Pfeiffer, Meryl Brod, Lori D McLeod and 4 more

The Journal of Clinical Endocrinology & Metabolism · 2026-03-17 · 111 (4) · 945-952

DOI: 10.1210/clinem/dgaf653 ↗

At a glance

Randomisierte kontrollierte Studie in The Journal of Clinical Endocrinology & Metabolism, published online on 2025-12-09. Written by Mishaela Rubin and 15 co-authors. Institution: Department of Endocrinology, Columbia University, New York, NY 10032, USA. Major MEDLINE topics: Hypoparathyroidism, Patient Reported Outcome Measures. Cited 5 times so far (Crossref); 37 references. The full text is freely available (open access, CC BY 4.0). Funded by: Ascendis Pharma Bone Diseases A/S.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Context

Individuals with hypoparathyroidism experience a range of physical and cognitive symptoms and reduced quality of life (QoL) despite management with conventional therapy (active vitamin D and calcium).

Objective

This analysis investigated the long-term impact of parathyroid hormone (PTH) replacement therapy with palopegteriparatide (YORVIPATH®) on symptoms, daily functioning, and well-being in adults with chronic hypoparathyroidism. Associations between patient characteristics and changes in patient-reported outcomes (PROs) were also analyzed.

Methods

PaTH Forward was a phase 2 clinical trial of palopegteriparatide with a 4-week randomized, double-blind, placebo-controlled period followed by an open-label extension period lasting through trial week 266. PRO measures were collected at baseline, weeks 4, 12, 26, 58, and annually thereafter through the end of the trial. The Hypoparathyroidism Patient Experience Scales (HPES) assess disease-specific symptoms and impacts on functioning and well-being. The Short Form Health Survey (SF-36v2) measures general health-related QoL. Data were analyzed using descriptive statistics and Mixed Models for Repeated Measures.

Results

Palopegteriparatide treatment demonstrated significant improvements from baseline in disease-specific symptoms and impacts on daily functioning and well-being at week 12, which were sustained through week 110. Mean changes in PROs met thresholds for clinically meaningful within-patient improvement. Significant improvements in general health-related QoL were also shown in SF-36v2 scores. Results were generally similar across demographics and patient characteristics.

Conclusion

Through week 110 of the PaTH Forward trial, PTH replacement therapy with palopegteriparatide was associated with significant improvements in disease-specific symptoms and impacts on daily functioning and well-being, as well as general health-related QoL.

Subjects

MeSH terms (MEDLINE)

HypoparathyroidismPatient Reported Outcome MeasuresHumansMaleFemaleMiddle AgedQuality of LifeAdultDouble-Blind MethodParathyroid HormoneAgedHormone Replacement TherapyTreatment Outcome

Author keywords

hypoparathyroidismpalopegteriparatidepatient-reported outcomesquality of life

Substances

Parathyroid Hormone

Authors and institutions

  • Department of Endocrinology, Columbia University, New York, NY 10032, USA.
  • Research Unit of Metabolic Bone and Thyroid Disorders, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.
  • Unit of Metabolic Bone and Thyroid Disorders, Fondazione Policlinico Universitario Campus Bio-Medico, 00128 Rome, Italy.
  • Department of Medicine - Endocrinology, The University of Chicago, Chicago, IL 60637, USA.
  • Department of Clinical Medicine, McMaster University, Hamilton, ON L8S 4L8, Canada.
  • Department of Endocrinology, Rigshospitalet and University of Copenhagen, 2100 Copenhagen, Denmark.

ORCID profiles: Andrea Palermo, Uberto Pagotto, Alden R Smith

Funding

  • Ascendis Pharma Bone Diseases A/S

Cite

APA

Rubin, M., Palermo, A., Vokes, T., Khan, A. A., Schwarz, P., Cetani, F., Pagotto, U., Tsourdi, E., Sikjaer, T., Pfeiffer, K. M., Brod, M., McLeod, L. D., Zhao, C., Noori, W., Shu, A. D., & Smith, A. R. (2026). Patient-reported outcomes in palopegteriparatide-treated adults with hypoparathyroidism: PaTH Forward trial extension. The Journal of Clinical Endocrinology & Metabolism, 111(4), 945-952. https://doi.org/10.1210/clinem/dgaf653

Vancouver

Rubin M, Palermo A, Vokes T, Khan AA, Schwarz P, Cetani F, et al. Patient-reported outcomes in palopegteriparatide-treated adults with hypoparathyroidism: PaTH Forward trial extension. The Journal of Clinical Endocrinology & Metabolism. 2026;111(4):945-952. doi:10.1210/clinem/dgaf653

BibTeX
@article{Rubin2026,
  author = {Rubin, Mishaela and Palermo, Andrea and Vokes, Tamara and Khan, Aliya A and Schwarz, Peter and Cetani, Filomena and Pagotto, Uberto and Tsourdi, Elena and Sikjaer, Tanja and Pfeiffer, Kathryn M and Brod, Meryl and McLeod, Lori D and Zhao, Carol and Noori, Wahidullah and Shu, Aimee D and Smith, Alden R},
  title = {Patient-reported outcomes in palopegteriparatide-treated adults with hypoparathyroidism: PaTH Forward trial extension},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  volume = {111},
  number = {4},
  pages = {945--952},
  doi = {10.1210/clinem/dgaf653}
}
Start for free →